Anastrozole

Anastrozole is usually known under the brand name “arimidex”. It was developed by an company “Zeneca Pharmaceuticals” and finally approved by the “Food and Drug Administration” in 1995. It belongs to the 3rd generation of aromatase inhibitors, which blocks the aromatase enzyme and lowering estrogen production in the human body. This makes it especially useful for handling hormone sensitive breast cancer in postmenopausal women. As part of the latest treatment option it has been generally recognized for its role in effectively aiming estrogen production.

Disclaimer: Information provided it this page is for general information only and does not substitute for professional medical advice.

For more details consult with your doctor or healthcare professional.